January 17th 2025
Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
An Examination of the Use of Patient Recruitment and Retention Tactics for Global Studies
March 18th 2024In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.
Patient and Site Personnel Perceptions of Retail Pharmacy Involvement in Clinical Research
March 7th 2024Despite industry-wide excitement over the involvement of retail pharmacies in clinical research, there is little information currently available on how retail pharmacies are perceived by investigative sites and patients.
Artificial Intelligence Drives Industry Response to Project Optimus
February 27th 2024The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
From Words to Action: Advancing Efforts to Reduce the Racial Gap in Clinical Research
February 7th 2024Despite repeated calls from the FDA, patient advocates, and scholars for the need to address demographic disparities in clinical research, White participants still remain overrepresented while racial minority participants remain underrepresented in clinical trials.